公开(公告)号：US11234995B2

公开(公告)日：2022-02-01

申请号：US16068163

申请日：2017-01-05

申请人： OSAKA UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION

发明人： Masayuki Nakamori ,  Hideki Mochizuki ,  Satoshi Obika ,  Takanori Yokota ,  Tetuya Nagata ,  Yuya Kasahara

IPC分类号： C12N15/11 ,  A61K31/712 ,  C07K14/47 ,  C12N15/113 ,  C07H21/02 ,  C12N15/09 ,  A61P25/28 ,  A61P25/16

摘要： The present invention can provide a nucleic acid medicine which has a higher effect and a more prolonged effect of inhibiting the expression of α-synudein can be provided. Disclosed is the oligonucleotide or a pharmacologically acceptable salt thereof, the oligonucleotide containing at least one nucleoside structure represented by Formula (I): (where each of Base and A are defined substituent or structure), can bind to an α-synudein gene, has activity for inhibiting expression of the α-synudein gene, and is complementary to the α-synudein gene, and the oligonucleotide has a length of twelve to twenty bases.

公开(公告)号：US12071624B2

公开(公告)日：2024-08-27

申请号：US17250806

申请日：2019-09-04

申请人： OSAKA UNIVERSITY ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION ,  NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY

发明人： Akira Kikuchi ,  Shinji Matsumoto ,  Satoshi Obika ,  Yuya Kasahara ,  Takumi Fukumoto

IPC分类号： C07H21/04 ,  A61P35/04 ,  C12N15/113

CPC分类号： C12N15/1137 ,  A61P35/04 ,  C12N2310/11 ,  C12N2310/315

摘要： The purpose of the present invention is to provide an antisense oligonucleotide that targets an ARL4C molecule and exerts an antitumor effect in vivo, and a nucleic acid drug using the antisense oligonucleotide. An antisense oligonucleotide that has a base sequence consisting of at least 10 consecutive bases contained in the base sequence represented by SEQ ID NO: 1. This antisense oligonucleotide targets an ARL4C molecule and thus can inhibit the expression of ARL4C in a tumor cell in vitro and suppress the migration and proliferation thereof. When systemically administered, moreover, the antisense oligonucleotide can exert an excellent antitumor effect in vivo too.

公开(公告)号：US11866705B2

公开(公告)日：2024-01-09

申请号：US17261653

申请日：2019-07-31

申请人： Osaka University ,  National Institutes of Biomedical Innovation, Health and Nutrition ,  Luxna Biotech Co., Ltd.

发明人： Masahito Shimojo ,  Satoshi Obika ,  Yuya Kasahara ,  Takao Suzuki ,  Masaki Yamagami ,  Tadashi Umemoto

IPC分类号： C12N15/113

CPC分类号： C12N15/113 ,  C12N2310/11 ,  C12N2310/3231

摘要： Disclosed is an oligonucleotide or a pharmacologically acceptable salt thereof, wherein the oligonucleotide comprises at least one defined nucleoside structure, can bind to a human nSR100 gene and has human nSR100 expression inhibiting activity. The oligonucleotide has a length of 12 to 20 mer, and is complementary to a defined target region. Further, disclosed is an nSR100 gene expression inhibitor and a cancer therapeutic agent containing the oligonucleotide or the pharmacologically acceptable salt thereof. The cancer therapeutic agent is used for treatment of small cell lung cancer, prostate cancer, or breast cancer.

公开(公告)号：US11479773B2

公开(公告)日：2022-10-25

申请号：US16498102

申请日：2018-02-20

申请人： Aichi Medical University ,  National Institutes of Biomedical Innovation, Health and Nutrition

发明人： Satoshi Obika ,  Yuya Kasahara ,  Kosei Takeuchi

IPC分类号： C12N15/113 ,  A61P25/00 ,  A61K31/7115

摘要： The present invention provides an antisense oligonucleotide for inhibiting biosynthesis of chondroitin sulfate. The antisense oligonucleotide comprises at least one modified nucleotide, wherein the antisense oligonucleotide suppresses expression of one or both of the chondroitin sulfate N-acetylgalactosaminyltransferase-1 (CSGalNAcT1) gene and the chondroitin sulfate N-acetylgalactosaminyltransferase-2 (CSGalNAcT2) gene.

公开(公告)号：US12104154B2

公开(公告)日：2024-10-01

申请号：US17666341

申请日：2022-02-07

申请人： Osaka University

发明人： Satoshi Obika ,  Reiko Waki ,  Takao Inoue ,  Tokuyuki Yoshida ,  Kunihiko Morihiro ,  Yuya Kasahara ,  Atsushi Mikami

IPC分类号： C12N15/113 ,  A61K31/7115 ,  A61K31/712

CPC分类号： C12N15/113 ,  A61K31/7115 ,  A61K31/712

摘要： The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2′,4′-bridged nucleic acids, 2′,4′-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2′,4′-non-bridged nucleic acid residue(s) is/are modified.

公开(公告)号：US11261440B2

公开(公告)日：2022-03-01

申请号：US16487762

申请日：2018-02-20

申请人： Osaka University

发明人： Satoshi Obika ,  Reiko Waki ,  Takao Inoue ,  Tokuyuki Yoshida ,  Kunihiko Morihiro ,  Yuya Kasahara ,  Atsushi Mikami

IPC分类号： C12N15/113 ,  A61K31/7115 ,  A61K31/712

摘要： The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2′,4′-bridged nucleic acids, 2′,4′-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2′,4′-non-bridged nucleic acid residue(s) is/are modified.